Joincare(SH:600380) Shen Zhen Shang Bao·2025-10-25 01:46Core Viewpoint - Health元 reported a decline in revenue and net profit for the third quarter of 2025, continuing a trend of decreasing performance over the past nine quarters [1][3]. Financial Performance - The company's revenue for Q3 2025 was 3.58 billion CNY, a year-on-year decrease of 2.3% [2]. - The net profit attributable to shareholders for Q3 2025 was 306 million CNY, down 8.6% year-on-year [2]. - The net profit after deducting non-recurring items was 288 million CNY, a decrease of 7.4% compared to the same period last year [2]. - The operating cash flow for the first nine months of 2025 was 3.00 billion CNY, an increase of 14.8% year-on-year [2]. - The earnings per share (EPS) for Q3 2025 was 0.1674 CNY [2]. Asset and Equity Position - As of the end of Q3 2025, the total assets of the company were 36.014 billion CNY, an increase of 0.8% from the end of the previous year [3]. - The net assets attributable to shareholders were 14.867 billion CNY, up 2.3% from the end of the previous year [3]. Credit Losses - The company reported credit impairment losses of 10.0742 million CNY for the first nine months of 2025, an increase from 797,200 CNY in the same period last year, attributed to increased expected credit losses on receivables [3]. Business Overview - Health元 focuses on the research, production, and sales of pharmaceutical products and health supplements, including chemical preparations, biological products, and traditional Chinese medicine [3]. - The company has been investing in R&D, particularly in clinical trials for new drugs, to drive product innovation and market expansion [3]. Market Performance - As of October 24, 2025, Health元's stock price closed at 12.1 CNY, down 1.22%, with a total market capitalization of 22.136 billion CNY [4][5].